Portfolio news BioAgilytix

BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis.

#BioAgilytix #acquisition #360biolabs
14 Oct '21

BioAgilytix Closes Acquisition of Australia-based 360biolabs

Following final government approval, 360biolabs, a BioAgilytix company, adds world-class virology & immunology expertise and LC/MS/MS small molecule capabilities to the company, enabling support of bioanalytical services across all geographies and development stages

Durham, NC, October 14, 2021 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, announced today that, following Australian Foreign Investment Review Board (“FIRB”) approval, it officially closed the purchase of 360biolabs. The acquisition of the company, now known as 360biolabs, a BioAgilytix company, expands BioAgilytix’s capabilities into first-in-human trials (FIH), early-phase clinical trials and adds additional capacity by joining 360biolabs’ internationally recognized quality systems in Melbourne and Brisbane with its existing laboratories in Durham, North Carolina; Boston, Massachusetts; San Diego, California and Hamburg, Germany.

Located in Australia’s biomedical and clinical research hubs, Victoria and Queensland, 360biolabs offers world-class virology and immunology expertise, with BSL 2 and 3 laboratories, biomarker and immune monitoring capabilities with a state-of-the-art flow cytometry suite, molecular biology PCR suite and expansive bioanalytical LC/MS/MS small molecule capabilities.

“We are delighted to announce the final close of the 360biolabs acquisition, as it’s such positive and exciting news for our global team and customers. Our expanded capacity, expertise and agility to now serve clients across all geographies is unprecedented,” said Jim Datin, President and CEO of BioAgilytix. “360biolabs’ leadership position in virology and immunology, plus their small molecule capabilities and locations in Melbourne and Brisbane, help make BioAgilytix an end-to-end bioanalytical force dedicated to helping generate new innovations and life-changing therapeutics for patients around the world.”   

“Our team is thrilled to formally join forces with BioAgilytix, as we already share so much culturally, from our mutual strong scientific track record to our commitment to quality science enabling innovative medicines to be developed for patients. Together we will provide an exceptional range of specialized assays and services to fulfill our clients’ high expectations on a global scale,” said Alistair Draffan, CEO of 360biolabs. “We have no doubt that the combined group is more than up to the task of tackling the world’s many health challenges, whether the pandemic or treatments for unmet clinical needs.”

About 360biolabs, a BioAgilytix company
360biolabs, a BioAgilytix company, is the leading and most comprehensive specialty laboratory in Australia and New Zealand region. Our expert pharmacokinetic (PK) and pharmacodynamic (PD) assay services support small molecule, biologic, vaccine and other innovative therapeutic solutions to human health. A world class and industry experienced technical team, known for their ability to successfully deliver technically challenging assays, 360biolabs supports global pharmaceutical and biotech companies in a diverse and growing range of therapeutics areas.

360biolabs delivers global regulatory compliant assays and reports following ISO/IEC 17025, ISO 15189, OECD GLP, GCLP and ICH GCP with a focus on quality. For more information, visit www.360biolabs.com.